BC Week In Review | Jun 23, 2008
Company News

Nile Therapeutics, Mayo Clinic deal

Nile received exclusive, worldwide rights to develop and commercialize the clinic’s CU-NP , which is in preclinical testing. Nile will develop the natriuretic peptide receptor B ( NPRB ) agonist and NPRA agonist for undisclosed cardiovascular and renal...
Items per page:
1 - 1 of 1